Home/Pipeline/KRAS inhibitor

KRAS inhibitor

Oncology

Preclinical/Phase 1Active (AACR 2024 presentation)

Key Facts

Indication

Oncology

Phase

Preclinical/Phase 1

Status

Active (AACR 2024 presentation)

Company

Risen Pharma Tech

About Risen Pharma Tech

Clinical-stage biotech developing small molecule and siRNA drugs for osteoarthritis, oncology, and Alzheimer's disease with international competitiveness.

View full company profile

Therapeutic Areas

Orthopedics Oncology Neuroscience

Other Oncology Drugs

Drug	Company	Phase	Status
Bi-XDC with PROTACs	Coherent Biopharma	IND-enabling	Active
Bi-XDC with RPT	Coherent Biopharma	Early-stage	Active
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Preclinical Projects	Zion Pharma	Preclinical	Active
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active
Bendamustine Intermediate	AR Life Science	Commercial	Active